ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1017

Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network

James Wei1, Shiow-Ing Wang2 and Ying-Li Lin2, 1Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China), 2Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China)

Meeting: ACR Convergence 2025

Keywords: Administrative Data, Comorbidity, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1007–1037) Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing herpes zoster (HZ). This study aimed to assess the effectiveness of recombinant zoster vaccine (RZV) in reducing both the incidence of HZ and all-cause mortality among individuals with RA.

Methods: We conducted a retrospective cohort study using data from the TriNetX U.S. Collaborative Network between October 1, 2017, and March 31, 2024. The study population consisted of RA patients who received RZV (RA-RZV cohort) and those who did not (RA control cohort). Propensity score matching (PSM) was employed to balance baseline characteristics between the groups, accounting for demographics, social economic status, lifestyles, medical utilization, comorbidities, and medications. The primary outcomes were the risk of HZ and all-cause mortality. PSM-adjusted hazard ratios (HRs) were calculated using Cox proportional hazards regression models. Kaplan-Meier curves and Log-Rank tests were used to evaluate survival differences.

Results: After PSM, each cohort included 21,046 individuals. The RA-RZV group demonstrated significantly lower risks of HZ (HR: 0.836, 95% CI: 0.738–0.947) and all-cause mortality (HR: 0.606, 95% CI: 0.561–0.654). The HZ risk reduction was more pronounced in patients aged 50-64 years (HR: 0.731, 95% CI: 0.610–0.876), females (HR: 0.791, 95% CI: 0.684–0.915), White (HR: 0.808, 95% CI: 0.696–0.937), and Black/African American participants (HR = 0.685; 95% CI = 0.481–0.976).

Conclusion: RZV vaccination is associated with a reduced risk of HZ and mortality among RA patients aged 50 years and older. RZV vaccination should be prioritized among eligible RA patients.

Supporting image 1 Kaplan-Meier curve of herpes zoster infection

Supporting image 2Kaplan-Meier curve of all-cause mortality

Supporting image 3Study flow of patients selection


Disclosures: J. Wei: None; S. Wang: None; Y. Lin: None.

To cite this abstract in AMA style:

Wei J, Wang S, Lin Y. Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/effectiveness-of-recombinant-zoster-vaccine-in-reducing-herpes-zoster-incidence-and-all-cause-mortality-among-rheumatoid-arthritis-patients-a-retrospective-cohort-study-of-21046-individuals-from-tri/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-of-recombinant-zoster-vaccine-in-reducing-herpes-zoster-incidence-and-all-cause-mortality-among-rheumatoid-arthritis-patients-a-retrospective-cohort-study-of-21046-individuals-from-tri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology